In 1949, Dr. George Brecher developed a stain called new methylene blue to identify immature erythrocytes (reticulocytes) based upon aggregations of RNA within disintegrating ribosomes.…
In 1949, Dr. George Brecher developed a stain called new methylene blue to identify immature erythrocytes (reticulocytes) based upon aggregations of RNA within disintegrating ribosomes. This RNA is at its highest level immediately after enucleation of the cell and continues to decrease until its complete absence in the fully mature erythrocyte. Reticulocytes are so named due to their mesh-like (reticular) network of ribosomal RNA which, after staining, is readily visible with a blue granulofilamentous appearance. The quantitative evaluation of reticulocytes in peripheral blood is an important test used in the assessment of erythropoiesis, bone marrow function, and anemia typing.
Who Else Makes It
Registered in Shandong.
Record
Regulatory record for Epredia | Listed by | Richard-Allan Scientific LLC, United States |
| FDA product code | GJH |
| Device type | Stain, Reticulocyte |
| Device class | Class 1 |
| Regulation | 21 CFR 864.1850 |
| Establishment | Contract manufacturer, Specification developer, Complaint-file establishment, Manufacturer |
| Premarket notification | Exempt |
| Record published | 2024-09-05 |
Specifications
Specifications | MRI safety | Labeling does not contain MRI Safety Information |
| Single use | Yes |
| Label carries | lot or batch number, expiry date, manufacturing date |
Source: U.S. FDA establishment registration and device listing records, public domain. Restructured for clarity and searchability. Not affiliated with or endorsed by the FDA. Records are records: nothing here is an offer of sale.